Organon & Co | OGN

Stock Price
10.38
Daily Change
0.70 7.23%
Monthly
19.04%
Yearly
-49.40%
Q3 Forecast
10.29

Peers Price Chg Day Year Date
Celltrion 169,000.00 -1,200.00 -0.71% -11.61% Sep/05
Cspc Pharmaceutical 11.19 0.36 3.32% 140.13% Sep/05
Sino Biopharmaceutical 8.91 0.52 6.20% 183.76% Sep/05
Kangmei Pharma 2.03 0 0% 15.34% Sep/05
Adcock Ingram Holdings 7,187.00 -13.00 -0.18% 10.77% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Divis Laboratories Ltd 6,009.00 -124.50 -2.03% 16.96% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Knight Therapeutics 6.44 0 0% 14.18% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Malin Corporation 8.00 0 0% 29.03% Sep/01
Merck 84.71 0.66 0.79% -28.14% Sep/05
Medical Developments International 0.58 -0.01 -0.86% 36.90% Sep/05
Neuren Pharmaceuticals 20.48 0.50 2.50% 51.03% Sep/05
Novartis 129.82 1.34 1.04% 11.22% Sep/05
Organigram Holdings 2.28 0.08 3.64% -4.20% Sep/05
Organon & Co 10.38 0.70 7.23% -49.40% Sep/05
Pharma Mar 88.40 -2.80 -3.07% 116.88% Sep/05
Qiagen NV 40.39 0.18 0.44% -1.38% Sep/06
Laboratorios Farma 59.65 -0.10 -0.17% -26.18% Sep/05
Sartorius 193.20 4.90 2.60% -23.42% Sep/06
Tilray 1.64 0.06 3.80% -25.45% Sep/05


Organon & Co traded at $10.38 this Friday September 5th, increasing $0.70 or 7.23 percent since the previous trading session. Looking back, over the last four weeks, Organon & Co gained 19.04 percent. Over the last 12 months, its price fell by 49.40 percent. Looking ahead, we forecast Organon & Co to be priced at 10.29 by the end of this quarter and at 10.04 in one year, according to Trading Economics global macro models projections and analysts expectations.

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women''s health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.